MicroPort® Co-organizes Training Program of 2017 Coronary Interventional Treatment Training Center – Shanghai Division

Shanghai, China – The training program of the 2017 Coronary Interventional Treatment Training Center – Shanghai Division was recently launched. This training program was jointly held by Shanghai Cardiac Interventional Quality Control Center and 11 Shanghai-based hospitals, and Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was the sole strategic partner. The training program aims to leverage the best faculty in Shanghai to teach existing and potential interventional physicians the most accurate and advanced theories and operative techniques and meanwhile to provide trainees with a platform for academic exchange.
 
This training program was jointly launched by Shanghai Cardiac Interventional Quality Control Center, Zhongshan Hospital of Fudan University, Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital, Renji Hospital of Shanghai Jiao Tong University School of Medicine, Changhai Hospital of the Second Military Medical University, Changzheng Hospital of the Second Military Medical University, Shanghai General Hospital, Shanghai Sixth People's Hospital, Shanghai Tenth People's Hospital, Xinhua Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai Oriental Hospital of Tongji University. A total of 104 doctors took part in the training program.
 
During the opening ceremony of the training program, Academician Junbo Ge of Zhongshan Hospital of Fudan University addressed a speech. He said, this training program was designed by the top and the most experienced cardiac interventional experts in Shanghai and it is expected that the trainees could make the best use of this opportunity to learn from the precious clinical experience of these experts and apply the knowledge to their daily work, so as to make contributions to the development of China's cardiac interventional industry. In his speech, he also showed gratitude to the effort of MicroPort® in supporting the training program of cardiovascular interventional treatment. He said, MicroPort® holds a leading position in the domestically made cardiovascular device industry in China, and its cardiovascular interventional devices, such as Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®"), showed excellent performance. Meanwhile, its second-generation fully bioresorbable scaffold Firesorb® Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb®") also demostrated promising clinical results.
 
This training program contained two lectures – "the basic method and lesion analysis of coronary angiography" and "the complications and prevention of coronary angiography," respectively given by Professor Xianxian Zhao and Professor Shaoping Chen of Changhai Hospital of the Second Military Medical University. The lectures delivered fruitful results and stimulated hot discussions between the lecturer and trainees.
 
As a frontier technology, percutaneous coronary intervention ("PCI") has saved an increasingly more patients suffering from coronary heart disease. According to the statistics released during the 20th China Cardiovascular Interventional Forum ("CCIF 2017") in April, the total number of interventional treatment of coronary heart disease in the Chinese mainland in 2016 stood at 666,495, representing 17.4% increase compared to 2015. In order to strengthen the management of cardiovascular disease interventional treatment to improve the treatment effect and safety, the National Health and Family Planning Commission of China started to set up coronary interventional treatment training centers in several cities since 2008 to help more Chinese physicians master advanced technologies of interventional treatment. It is the fourth year for MicroPort® to engage in such training program as the only co-organizer in Shanghai. Lei Jiang, First Vice President of Domestic Coronary Sales & Marketing, said:" As a leader among domestic coronary stent producers, MicroPort® will continue to actively participate in training programs of coronary disease interventional treatment, to help build a communication platform for physicians and enhance the diagnosis and treatment of coronary disease, and thereby to benefit more patients."